Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Gains from Investment Securities (2016 - 2025)

BioCorRx's Gains from Investment Securities history spans 8 years, with the latest figure at $1.6 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, changed N/A, while the annual FY2024 figure was $1.4 million, 53.97% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $1.6 million at BioCorRx, up from $891443.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.6 million in Q3 2025 and bottomed at $815351.0 in Q4 2021.
  • The 3-year median for Gains from Investment Securities is $882869.0 (2023), against an average of $1.0 million.